While the world chases the next CAR-T breakthrough, the real battle isn't in the lab—it's on the factory floor. Avectas isn't making therapies; they're making the tools to manufacture them at scale, targeting the critical cost and scalability issues that plague the entire industry.

"The bottleneck isn't discovering cell therapies; it's manufacturing them affordably. Avectas is building the essential infrastructure to cross that chasm."

The leadership team, led by CEO Michael Maguire and Founder CSO Shirley O'Dea, is structured for technical execution. The presence of senior roles in Process Engineering and Analytical Development (Shane Finnegan, Lisa O'Flynn) underscores that this is an engineering-first company. They aren't chasing hype cycles; they're solving the gritty, high-value problems of yield and purity in cell manufacturing.

• Proprietary Solupore® tech targets the $100K+ cost barrier of cell therapy manufacturing.
• Strategic partnership with Sony Biotechnology validates platform scalability and integration potential.
• Lean team (59 employees) focused on core IP and B2B licensing, not direct-to-consumer marketing.